JHS Svendgaard Laboratories announced no deviation in the use of funds raised through a preferential issue totaling Rs. 29.99 crores for the quarter ended September 30, 2024, with Rs. 19.99 crores from equity shares and Rs. 9.99 crores from convertible warrants.